Friday 6 November 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue: −0.28%
EPS: −154.6%
Free cash flow: +38.8%
Total debt: −89.4%

Quarter to September 2026, against a year earlier

19.69 0.72 +3.80%

Follow VTRS

Alert me

Market cap: $21.8B
P/E: 0.0×
Fwd P/E: 82.6×
Dividend yield: 2.54%
F-score: 4/9
Altman Z: 0.61
Beneish M: −3.29
Dividend safety: 37/100

Overview Business Profile Earnings & Analysis Valuation Filings

Viatris Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 6, 2026 · accepted 4:04 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov